{"originalText": "，缘于入院1月余前于我院诊为降结肠中分化管状腺癌，于2016年03月04日在全麻上行“腹腔镜上根治性右半结肠切除术”，术后病理（N201601905），：（右半结肠），：结肠溃疡型中分化管状腺癌，侵犯肠壁全层及肠周脂肪组织，侵犯神经、脉管组织，手术标本双切端及另送(上切端)均未见癌浸润,另送(下切端)浆膜外纤维脂肪组织中见癌浸润。找到肠周淋巴结5/15个见癌转移。另送(右结肠根部淋巴结)、(结肠中血管右支根部淋巴结)镜上为纤维、血管、脂肪组织。（MN20160037），：该病例未检测到BRAF基因V600E突变。（MN20160037），：该病例检测到KRAS基因12号密码子G12S突变。术顺安返，予预防性抗感染、制酸、提高免疫力、营养支持等治疗好转后出院。于2016.04.12予“安维汀200MGIVGTTD1+奥沙利铂120MGIVGTTD2+氟尿嘧啶3400MGCIV48H+亚叶酸钙300MGIVGTTD1-2”方案化疗1个周期，化疗过程顺利，化疗后未见明显不良反应。此次为化疗再次就诊我院，门诊拟结肠癌术后收入院。下次出院以来精神、睡眠、饮食可，无腹痛、腹胀、发热，大小便正常，体重较前无明显变化。", "entities": [{"label_type": "疾病和诊断", "overlap": 0, "start_pos": 14, "end_pos": 24}, {"end_pos": 57, "label_type": "手术", "overlap": 0, "start_pos": 43}, {"end_pos": 82, "label_type": "解剖部位", "overlap": 0, "start_pos": 78}, {"label_type": "疾病和诊断", "overlap": 0, "start_pos": 85, "end_pos": 97}, {"label_type": "解剖部位", "overlap": 0, "start_pos": 100, "end_pos": 101}, {"label_type": "解剖部位", "overlap": 0, "start_pos": 105, "end_pos": 106}, {"end_pos": 173, "label_type": "解剖部位", "overlap": 0, "start_pos": 168}, {"end_pos": 194, "label_type": "解剖部位", "overlap": 0, "start_pos": 185}, {"end_pos": 209, "label_type": "解剖部位", "overlap": 0, "start_pos": 197}, {"end_pos": 349, "label_type": "药物", "overlap": 0, "start_pos": 346}, {"end_pos": 366, "label_type": "药物", "overlap": 0, "start_pos": 362}, {"end_pos": 383, "label_type": "药物", "overlap": 0, "start_pos": 379}, {"end_pos": 400, "label_type": "药物", "overlap": 0, "start_pos": 396}, {"label_type": "疾病和诊断", "overlap": 0, "start_pos": 458, "end_pos": 463}, {"end_pos": 485, "label_type": "解剖部位", "overlap": 0, "start_pos": 484}, {"end_pos": 488, "label_type": "解剖部位", "overlap": 0, "start_pos": 487}]}
